Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v4-FR | Version v4-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2018-05-07 | 2018-05-07 |
| Drug Identification Number | 02447711 | 02447711 |
| Brand name | TECHNIVIE | TECHNIVIE |
| Common or Proper name | TECHNIVIE 12.5/75/50 MG | TECHNIVIE 12.5/75/50 MG |
| Company Name | ABBVIE CORPORATION | ABBVIE CORPORATION |
| Ingredients | Ombitasvir Paritaprevir RITONAVIR | Ombitasvir Paritaprevir RITONAVIR |
| Strength(s) | 12.5MG 75MG 50MG | 12.5MG 75MG 50MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL | ORAL |
| Packaging size | 4 inner cartonsx7blisters | 4 inner cartonsx7blisters |
| ATC code | J05AX | J05AX |
| ATC description | DIRECT ACTING ANTIVIRALS | DIRECT ACTING ANTIVIRALS |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | ||
| Actual discontinuation date | 2017-11-30 | 2017-11-30 |
| Remaining supply date | 2018-06-30 | 2018-06-30 |
| Discontinuation status | Discontinued | Discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | This decision follows Health Canada’s recent approval of MAVIRET Tablets, AbbVie’s new pan-genotypic antiviral for the treatment of adults with chronic hepatitis C virus (HCV), which will replace HOLKIRA PAK, TECHNIVIE and MODERIBA on the Canadian market. | This decision follows Health Canada’s recent approval of MAVIRET Tablets, AbbVie’s new pan-genotypic antiviral for the treatment of adults with chronic hepatitis C virus (HCV), which will replace HOLKIRA PAK, TECHNIVIE and MODERIBA on the Canadian market. |
| Health Canada comments |